Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

NEW YORK, January 07, 2025--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage ... potential monthly dose. Weight loss was dose-dependent, with substantial reductions in mean body weight of 11.3 ...

Weight loss was dose-dependent ... M.D., Chief Medical Officer of Metsera. “The powerful reductions in weight affirm our earlier studies. We are also excited by the emerging tolerability ...